GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nykode Therapeutics AS (OTCPK:VACBF) » Definitions » EV-to-FCF

VACBF (Nykode Therapeutics AS) EV-to-FCF : 0.79 (As of Mar. 25, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Nykode Therapeutics AS EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nykode Therapeutics AS's Enterprise Value is $-40.65 Mil. Nykode Therapeutics AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-51.29 Mil. Therefore, Nykode Therapeutics AS's EV-to-FCF for today is 0.79.

The historical rank and industry rank for Nykode Therapeutics AS's EV-to-FCF or its related term are showing as below:

VACBF' s EV-to-FCF Range Over the Past 10 Years
Min: -36.19   Med: 0.73   Max: 2350.46
Current: 0.89

During the past 8 years, the highest EV-to-FCF of Nykode Therapeutics AS was 2350.46. The lowest was -36.19. And the median was 0.73.

VACBF's EV-to-FCF is ranked better than
64.39% of 424 companies
in the Biotechnology industry
Industry Median: 3.285 vs VACBF: 0.89

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-25), Nykode Therapeutics AS's stock price is $0.217. Nykode Therapeutics AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.120. Therefore, Nykode Therapeutics AS's PE Ratio (TTM) for today is At Loss.


Nykode Therapeutics AS EV-to-FCF Historical Data

The historical data trend for Nykode Therapeutics AS's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nykode Therapeutics AS EV-to-FCF Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial 12.46 8,388.08 -27.32 -5.14 0.45

Nykode Therapeutics AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.14 -3.47 -3.83 -0.24 0.45

Competitive Comparison of Nykode Therapeutics AS's EV-to-FCF

For the Biotechnology subindustry, Nykode Therapeutics AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nykode Therapeutics AS's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Nykode Therapeutics AS's EV-to-FCF falls into.



Nykode Therapeutics AS EV-to-FCF Calculation

Nykode Therapeutics AS's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-40.651/-51.291
=0.79

Nykode Therapeutics AS's current Enterprise Value is $-40.65 Mil.
Nykode Therapeutics AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nykode Therapeutics AS  (OTCPK:VACBF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Nykode Therapeutics AS's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.217/-0.120
=At Loss

Nykode Therapeutics AS's share price for today is $0.217.
Nykode Therapeutics AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.120.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Nykode Therapeutics AS EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Nykode Therapeutics AS's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nykode Therapeutics AS Business Description

Traded in Other Exchanges
Address
Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need.